+966 568813716 [email protected]

The Blog

Home / Page 33
03
Dec
2016
Risperidone (Risperdal®)
Posted On December 3, 2016  By Dr.Adel Serag  And has No Comment

Risperidone (US brand name Risperdal® and generic) is a second-generation (“atypical”) antipsychotic. Here is basic information about this medication. FDA-approved indications 1. Treatment of schizophrenia 2. As monotherapy or adjunctive therapy with lithium or valproate, for the treatment of acute manic or mixed episodes associated with Bipolar I […]

Read More

03
Dec
2016
Risperidone long-acting (Risperdal Consta®)
Posted On December 3, 2016  By Dr.Adel Serag  And has No Comment

Risperdal Consta® is a long-acting injectable formulation of risperidone, a second-generation (“atypical”) antipsychotic. Here is basic information about this medication. FDA-Approved Indications Schizophrenia Monotherapy for the maintenance treatment of Bipolar I Disorder Adjunctive therapy to lithium or valproate for the maintenance treatment of Bipolar I Disorder. […]

Read More

03
Dec
2016
3-month paliperidone palmitate (Invega Trinza®)
Posted On December 3, 2016  By Dr.Adel Serag  And has No Comment

Paliperidone palmitate (Invega Trinza®) is an extended-release injectable second-generation (“atypical”) antipsychotic which can be administered once every 3 months. Here is basic information about this medication. FDA-Approved Indication Schizophrenia after adequate treatment with 1-month paliperidone palmitate extended-release (Invega Sustenna®) for at least four months. Dosage The dose of 3-month […]

Read More

03
Dec
2016
Paliperidone palmitate (Invega Sustenna®)
Posted On December 3, 2016  By Dr.Adel Serag  And has No Comment

Paliperidone palmitate (Invega Sustenna®) is an extended-release injectable second-generation (“atypical”) antipsychotic. Here is basic information about this medication. FDA-approved indications Treatment of schizophrenia Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers or antidepressants Dosage A. Schizophrenia Initiation (IM deltoid): Administer 234 mg […]

Read More

03
Dec
2016
Extended Release Olanzapine (Zyprexa Relprevv®)
Posted On December 3, 2016  By Dr.Adel Serag  And has No Comment

Extended Release Olanzapine (Zyprexa Relprevv®) is a long-acting, second-generation (atypical), injectable antipsychotic. Here is basic information about this medication. FDA-approved indications Schizophrenia Dosage Recommended dosing of extended release olanzapine based on correspondence to oral olanzapine doses A. First 8 weeks of treatment a) Target oral dose 10 mg/day: 210 […]

Read More

03
Dec
2016
Haloperidol (Haldol® Decanoate)
Posted On December 3, 2016  By Dr.Adel Serag  And has No Comment

Haldol® Decanoate is a brand name of a depot formulation of haloperidol which is a first-generation (“typical”) antipsychotic. Here is basic information about this medication. FDA-approved indications Treatment of schizophrenic patients who require prolonged parenteral antipsychotic therapy Dosage A. Initial dosage (given by deep IM injection […]

Read More

01
Dec
2016
Top 10 Meditation tools
Posted On December 1, 2016  By Dr.Adel Serag  And has No Comment

Read More

01
Dec
2016
Ziprasidone (Geodon®)
Posted On December 1, 2016  By Dr.Adel Serag  And has No Comment

Ziprasidone (US brand name Geodon® and generic) is a second-generation (“atypical”) antipsychotic. FDA-approved indications A. As an oral formulation 1. Schizophrenia 2. Acute treatment as monotherapy of manic or mixed episodes associated with bipolar I disorder 3. Maintenance treatment of bipolar I disorder as an adjunct […]

Read More

01
Dec
2016
Lurasidone (Latuda®)
Posted On December 1, 2016  By Dr.Adel Serag  And has No Comment

Lurasidone or Latuda® is a second-generation antipsychotic, manufactured by Sunovion and introduced in the US in 2010 for the acute treatment of schizophrenia. Note: This page and its related pages contain the full text of the chapter on lurasidone (Latuda) in my book, The Latest Antidepressants. This webpage […]

Read More

01
Dec
2016
Iloperidone (Fanapt®): Basic Information
Posted On December 1, 2016  By Dr.Adel Serag  And has No Comment

Iloperidone (US brand name Fanapt®) is a second-generation (“atypical”) antipsychotic. FDA-approved indications Treatment of adults with schizophrenia Dosage Starting: 1 mg twice daily Target: 6–12 mg twice daily (achieved by dose increments of 1–2 mg twice daily) Maximum: 12 mg twice daily (24 mg/day) Please refer […]

Read More

Page 33 of 89